Predictimmune is a molecular diagnostics company developing pioneering tools for guiding treatment options in immune-mediated inflammatory diseases. At diagnosis there is no way of knowing whether a patient is likely to experience a severe, relapsing form of the disease or a more quiescent and easier to manage pathway. The ability to stratify patients at the point of diagnosis will identify patients who may benefit from first line treatment with state-of-the-art anti-inflammatory drugs (biologics).